Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
2019 · Nature Medicine · 1,066 citations
https://doi.org/10.1038/s41591-019-0654-5
I
Imke Satzger
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
93
Papers
4.6K
Citations
34
h-index
54
i10-index
Imke Satzger is an academic researcher. The author has contributed to research in topics: Cutaneous Melanoma Detection and Management & Nonmelanoma Skin Cancer Studies & Melanoma and MAPK Pathways. The author has an h-index of 34, co-authored 80 publications.
ORCID: 0000-0001-5983-2125Papers by this author
worksThe hand‐foot‐syndrome associated with medical tumor therapy – classification and management
2010 · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 157 citations
https://doi.org/10.1111/j.1610-0387.2010.07449.x
Non‐melanoma skin cancer is reduced after switch of immunosuppression to mTOR‐inhibitors in organ transplant recipients
2014 · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 68 citations
https://doi.org/10.1111/ddg.12355
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
2019 · Cancer Immunology Immunotherapy · 56 citations
https://doi.org/10.1007/s00262-019-02353-5
Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?
2015 · Melanoma Research · 29 citations
https://doi.org/10.1097/cmr.0000000000000169
Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers?
2010 · Dermatology · 20 citations
https://doi.org/10.1159/000317081
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat